Timothy Y Y Lai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6143733/publications.pdf

Version: 2024-02-01

253 papers 14,592 citations

20759 60 h-index 109 g-index

262 all docs 262 docs citations

times ranked

262

8111 citing authors

#	Article	IF	CITATIONS
1	OCT-based biomarkers for predicting treatment response in eyes with centre-involved diabetic macular oedema treated with anti-VEGF injections: a real-life retina clinic-based study. British Journal of Ophthalmology, 2023, 107, 525-533.	2.1	15
2	Clinically relevant factors associated with a binary outcome of diabetic macular ischaemia: an OCTA study. British Journal of Ophthalmology, 2023, 107, 1311-1318.	2.1	6
3	Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization. Expert Opinion on Drug Safety, 2022, 21, 43-54.	1.0	9
4	Evolving treatment paradigms for PCV. Eye, 2022, 36, 257-265.	1.1	23
5	Visualising the choriocapillaris: Histology, imaging modalities and clinical research ―A review. Clinical and Experimental Ophthalmology, 2022, 50, 91-103.	1.3	6
6	Recommendations of the treat-and-extend regimen for neovascular age-related macular degeneration: 2020 updates. Hong Kong Journal of Ophthalmology: the Official Publication of the College of Ophthalmologists of Hong Kong = Xianggang Yan Ke Xue Kan: Xianggang Yan Ke Yi Xue Yuan, 2022, 25, 39-46.	0.3	1
7	Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet, The, 2022, 399, 729-740.	6.3	190
8	Insights Into the Global Epidemic of High Myopia and Its Implications. JAMA Ophthalmology, 2022, 140, 123.	1.4	4
9	Optical Coherence Tomography Classification Systems for Diabetic Macular Edema and Their Associations With Visual Outcome and Treatment Responses – An Updated Review. Asia-Pacific Journal of Ophthalmology, 2022, 11, 247-257.	1.3	17
10	RANIBIZUMAB 0.5 MG TREATMENT IN ADOLESCENTS WITH CHOROIDAL NEOVASCULARIZATION: SUBGROUP ANALYSIS DATA FROM THE MINERVA STUDY. Retinal Cases and Brief Reports, 2021, 15, 348-355.	0.3	4
11	Polypoidal Choroidal Vasculopathy. Ophthalmology, 2021, 128, 443-452.	2.5	261
12	Pachychoroid: current concepts on clinical features and pathogenesis. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 1385-1400.	1.0	40
13	Ocular imaging at the cutting-edge. Eye, 2021, 35, 1-3.	1.1	7
14	THE ANGIOPOIETIN/TIE PATHWAY IN RETINAL VASCULAR DISEASES. Retina, 2021, 41, 1-19.	1.0	44
15	IMI Pathologic Myopia., 2021, 62, 5.		140
16	Optical Coherence Tomography Angiography Compared with Multimodal Imaging for Diagnosing Neovascular Central Serous Chorioretinopathy. American Journal of Ophthalmology, 2021, 232, 70-82.	1.7	10
17	Reply. Ophthalmology Retina, 2021, 5, e41-e42.	1.2	О
18	Reply. Retina, 2021, 41, e56-e58.	1.0	0

#	Article	IF	CITATIONS
19	Non-ICGA treatment criteria for Suboptimal Anti-VEGF Response for Polypoidal Choroidal Vasculopathy: APOIS PCV Workgroup Report 2. Ophthalmology Retina, 2021, 5, 945-953.	1.2	20
20	RANIBIZUMAB WITH OR WITHOUT VERTEPORFIN PHOTODYNAMIC THERAPY FOR POLYPOIDAL CHOROIDAL VASCULOPATHY. Retina, 2021, 41, 387-392.	1.0	8
21	Association between Retinal Thickness Variability and Visual Acuity Outcome during Maintenance Therapy Using Intravitreal Anti-Vascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration. Journal of Personalized Medicine, 2021, 11, 1024.	1.1	6
22	Treat-and-Extend Regimens for the Management of Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy: Consensus and Recommendations From the Asia-Pacific Vitreo-retina Society. Asia-Pacific Journal of Ophthalmology, 2021, 10, 507-518.	1.3	19
23	Impact of the LEAVO Study in Asia. Eye, 2020, 34, 211-212.	1.1	O
24	REAL-WORLD EFFECTIVENESS AND SAFETY OF RANIBIZUMAB TREATMENT IN PATIENTS WITH AND WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY. Retina, 2020, 40, 1529-1539.	1.0	10
25	Ranibizumab for myopic choroidal neovascularization. Expert Opinion on Biological Therapy, 2020, 20, 1385-1393.	1.4	14
26	Re: Chloroquine (CQ) and Hydroxychloroquine (HQ) Retinal Toxicity Consideration in the Treatment of the Coronavirus Disease 2019 (COVID-19). Asia-Pacific Journal of Ophthalmology, 2020, 9, 375-376.	1.3	0
27	Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy. JAMA Ophthalmology, 2020, 138, 935.	1.4	93
28	Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19. Asia-Pacific Journal of Ophthalmology, 2020, 9, 85-87.	1.3	28
29	Latest Developments in Polypoidal Choroidal Vasculopathy: Epidemiology, Etiology, Diagnosis, and Treatment. Asia-Pacific Journal of Ophthalmology, 2020, 9, 260-268.	1.3	21
30	Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Results from the LUMINOUS study. PLoS ONE, 2020, 15, e0227557.	1.1	18
31	Managing Uveitis during the COVID-19 Pandemic. Ophthalmology, 2020, 127, e65-e67.	2.5	20
32	Clinical Trials Related to Myopic Choroidal Neovascularization. , 2020, , 283-295.		1
33	Polypoidal Choroidal Vasculopathy. Retina Atlas, 2020, , 29-37.	0.0	0
34	Pachychoroid disease. Eye, 2019, 33, 14-33.	1.1	443
35	Identification and characterization of a novel promoter variant in placental growth factor for neovascular age-related macular degeneration. Experimental Eye Research, 2019, 187, 107748.	1.2	2
36	Experience of using adalimumab in treating sight-threatening paediatric or adolescent Behcet's disease-related uveitis. Journal of Ophthalmic Inflammation and Infection, 2019, 9, 14.	1.2	16

#	Article	IF	CITATIONS
37	Central serous chorioretinopathy: Towards an evidence-based treatment guideline. Progress in Retinal and Eye Research, 2019, 73, 100770.	7.3	276
38	Reply. Ophthalmology, 2019, 126, e45-e46.	2.5	0
39	Asian perspective of eye diseases. Eye, 2019, 33, 1-2.	1.1	0
40	Reply. Ophthalmology, 2019, 126, e43-e44.	2.5	0
41	RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY IN ASIAN PATIENTS WITH MYOPIC CHOROIDAL NEOVASCULARIZATION. Retina, 2019, 39, 1985-1994.	1.0	26
42	Evaluation of the association of C5 with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Eye and Vision (London, England), 2019, 6, 34.	1.4	8
43	EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB IN ASIAN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2019, 39, 537-547.	1.0	8
44	Pharmacotherapy for Choroidal Neovascularization Due to Uncommon Causes. Current Pharmaceutical Design, 2019, 24, 4882-4895.	0.9	4
45	An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 963-973.	1.0	11
46	Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes. Ophthalmology, 2018, 125, 850-862.	2.5	25
47	Polypoidal Choroidal Vasculopathy. Ophthalmology, 2018, 125, 708-724.	2.5	282
48	Diabetic macular oedema: evidenceâ€based treatment recommendations for Asian countries. Clinical and Experimental Ophthalmology, 2018, 46, 75-86.	1.3	21
49	Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia. Progress in Retinal and Eye Research, 2018, 63, 92-106.	7.3	125
50	LONG-TERM OUTCOMES OF RANIBIZUMAB TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION IN EAST-ASIAN PATIENTS FROM THE RADIANCE STUDY. Retina, 2018, 38, 2228-2238.	1.0	32
51	EFFICACY AND SAFETY OF RANIBIZUMAB FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION DUE TO UNCOMMON CAUSE. Retina, 2018, 38, 1464-1477.	1.0	99
52	Treatment of Punctate Inner Choroidopathy with Choroidal Neovascularization Using Corticosteroid and Intravitreal Ranibizumab. BioMed Research International, 2018, 2018, 1-7.	0.9	11
53	Baseline Predictors of Visual Acuity Outcome in Patients with Wet Age-Related Macular Degeneration. BioMed Research International, 2018, 2018, 1-10.	0.9	24
54	Impact of virtual reality simulation on learning barriers of phacoemulsification perceived by residents. Clinical Ophthalmology, 2018, Volume 12, 885-893.	0.9	17

#	Article	IF	Citations
55	Current management strategy of polypoidal choroidal vasculopathy. Indian Journal of Ophthalmology, 2018, 66, 1727.	0.5	17
56	Choroidal structures in polypoidal choroidal vasculopathy, neovascular age-related maculopathy, and healthy eyes determined by binarization of swept source optical coherence tomographic images. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 935-943.	1.0	37
57	The potential of spectral domain optical coherence tomography imaging based retinal biomarkers. International Journal of Retina and Vitreous, 2017, 3, 1.	0.9	61
58	Fundus Autofluorescence Imaging in the Assessment of Acute Zonal Occult Outer Retinopathy. Ophthalmologica, 2017, 237, 153-158.	1.0	11
59	Reply. Ophthalmology, 2017, 124, e29-e30.	2.5	0
60	Elevated angiopoietin 2 in aqueous of patients with neovascular age related macular degeneration correlates with disease severity at presentation. Scientific Reports, 2017, 7, 45081.	1.6	37
61	Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy. JAMA Ophthalmology, 2017, 135, 1206.	1.4	241
62	Myopic Choroidal Neovascularization. Ophthalmology, 2017, 124, 1690-1711.	2.5	263
63	Central Serous Chorioretinopathy. , 2017, , 227-251.		2
64	An Update on Intravitreal Aflibercept in Treating Macular Diseases. Asia-Pacific Journal of Ophthalmology, 2017, 6, 225-227.	1.3	1
65	Anti-VEGF Therapy for Neovascular AMD and Polypoidal Choroidal Vasculopathy. Asia-Pacific Journal of Ophthalmology, 2017, 6, 527-534.	1.3	29
66	Anti–Vascular Endothelial Growth Factor Therapy for Myopic Choroidal Neovascularization. Asia-Pacific Journal of Ophthalmology, 2017, 6, 554-560.	1.3	5
67	Ophthalmic Application of Anti-VEGF Therapy. Asia-Pacific Journal of Ophthalmology, 2017, 6, 479-480.	1.3	6
68	Identification of $\langle i \rangle$ ANGPT2 $\langle j i \rangle$ as a New Gene for Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in the Chinese and Japanese Populations., 2017, 58, 1076.		29
69	Classification of Exudative Age-Related Macular Degeneration With Pachyvessels on En Face Swept-Source Optical Coherence Tomography. , 2017, 58, 1054.		21
70	Ophthalmic Application of Anti-VEGF Therapy. Asia-Pacific Journal of Ophthalmology, 2017, 6, .	1.3	5
71	Alveolar rhabdomyosarcoma of the sphenoid sinus mimicking optic neuritis presenting with intermittent visual loss in an adult. OncoTargets and Therapy, 2016, Volume 9, 6333-6336.	1.0	3
72	Association of <i>ABCG1</i> With Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Chinese and Japanese., 2016, 57, 5758.		11

#	Article	IF	Citations
73	Identification of $\langle i \rangle$ PGF $\langle i \rangle$ as a New Gene for Neovascular Age-Related Macular Degeneration in a Chinese Population. , 2016, 57, 1714.		19
74	Genetics of Bietti Crystalline Dystrophy. Asia-Pacific Journal of Ophthalmology, 2016, 5, 245-252.	1.3	34
75	The Rate of Endophthalmitis After Intravitreal Injections. Asia-Pacific Journal of Ophthalmology, 2016, 5, 165-166.	1.3	0
76	Ranibizumab in Myopic Choroidal Neovascularization: A Subgroup Analysis by Ethnicity, Age, and Ocular Characteristics in RADIANCE. Ophthalmologica, 2016, 236, 19-28.	1.0	20
77	Choroidal thickness in Chinese patients with non-arteritic anterior ischemic optic neuropathy. BMC Ophthalmology, 2016, 16, 153.	0.6	8
78	MYOPIC CHOROIDAL NEOVASCULARIZATION. Retina, 2016, 36, 1614-1621.	1.0	37
79	Advances of optical coherence tomography in myopia and pathologic myopia. Eye, 2016, 30, 901-916.	1.1	70
80	A missense variant in FGD6 confers increased risk of polypoidal choroidal vasculopathy. Nature Genetics, 2016, 48, 640-647.	9.4	68
81	Surgical treatment for diabetic vitreoretinal diseases: a review. Clinical and Experimental Ophthalmology, 2016, 44, 340-354.	1.3	42
82	HTRA1 promoter variant differentiates polypoidal choroidal vasculopathy from exudative age-related macular degeneration. Scientific Reports, 2016, 6, 28639.	1.6	24
83	Spectral Domain Optical Coherence Tomography Features and Classification Systems for Diabetic Macular Edema. Asia-Pacific Journal of Ophthalmology, 2016, 5, 360-367.	1.3	23
84	Updates of pathologic myopia. Progress in Retinal and Eye Research, 2016, 52, 156-187.	7.3	380
85	Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016) Tj ETQq1 1 0.7845	314 rgBT / 2.5	Overlock 10
86	Ethnic differences in the association of SERPING1 with age-related macular degeneration and polypoidal choroidal vasculopathy. Scientific Reports, 2015, 5, 9424.	1.6	27
87	Intravitreal Injection—Technique and Safety. Asia-Pacific Journal of Ophthalmology, 2015, 4, 321-328.	1.3	40
88	The REVEAL Study. Ophthalmology, 2015, 122, 1402-1415.	2.5	149
89	New loci and coding variants confer risk for age-related macular degeneration in East Asians. Nature Communications, 2015, 6, 6063.	5.8	147
90	The natural history of polypoidal choroidal vasculopathy: a multi-center series of untreated Asian patients. Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253, 2075-2085.	1.0	53

#	Article	IF	Citations
91	Neuroprotective effect of epigallocatechin-3-gallate in a mouse model of chronic glaucoma. Neuroscience Letters, 2015, 600, 132-136.	1.0	41
92	Myopic choroidal neovascularisation: current concepts and update on clinical management. British Journal of Ophthalmology, 2015, 99, 289-296.	2.1	135
93	Focal choroidal excavation in patients with central serous chorioretinopathy. Eye, 2015, 29, 453-459.	1.1	21
94	Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis). Transactions of the American Ophthalmological Society, 2015, 113, T8.	1.4	14
95	Photoreceptor inner segment ellipsoid band integrity on spectral domain optical coherence tomography. Clinical Ophthalmology, 2014, 8, 2507.	0.9	42
96	Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma. Journal of Ophthalmology, 2014, 2014, 1-8.	0.6	18
97	FPR1 interacts with CFH, HTRA1 and smoking in exudative age-related macular degeneration and polypoidal choroidal vasculopathy. Eye, 2014, 28, 1502-1510.	1.1	24
98	UNDERSTANDING INDOCYANINE GREEN ANGIOGRAPHY IN POLYPOIDAL CHOROIDAL VASCULOPATHY. Retina, 2014, 34, 2397-2406.	1.0	34
99	Letter to the Editor Regarding "The Endophthalmitis Kit― Asia-Pacific Journal of Ophthalmology, 2014, 3, 130.	1.3	0
100	THE ROLES OF GENETIC FACTORS IN UVEITIS AND THEIR CLINICAL SIGNIFICANCE. Retina, 2014, 34, 1-11.	1.0	39
101	Machines and Cutters: Stellaris PC. Developments in Ophthalmology, 2014, 54, 8-16.	0.1	2
102	Genes in the High-Density Lipoprotein Metabolic Pathway in Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy. Ophthalmology, 2014, 121, 911-916.	2.5	56
103	Influence of molecular genetics in Vogt-Koyanagi-Harada disease. Journal of Ophthalmic Inflammation and Infection, 2014, 4, 20.	1.2	32
104	Gender specific association of a complement component 3 polymorphism with polypoidal choroidal vasculopathy. Scientific Reports, 2014, 4, 7018.	1.6	27
105	Associations of the C2-CFB-RDBP-SKIV2L Locus with Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy. Ophthalmology, 2013, 120, 837-843.	2.5	38
106	Contribution of SNRNP200 sequence variations to retinitis pigmentosa. Eye, 2013, 27, 1204-1213.	1.1	15
107	Clinical Characteristics of Intermediate Uveitis in Chinese Patients. Ocular Immunology and Inflammation, 2013, 21, 71-76.	1.0	13
108	What's New in Uveitis and Ocular Inflammation?. Asia-Pacific Journal of Ophthalmology, 2013, 2, 139-140.	1.3	2

#	Article	IF	CITATIONS
109	Association of <i>CFH </i>) and <i>SERPING1 </i>) polymorphisms with anterior uveitis. British Journal of Ophthalmology, 2013, 97, 1475-1480.	2.1	16
110	Targeted Sequencing of 179 Genes Associated with Hereditary Retinal Dystrophies and 10 Candidate Genes Identifies Novel and Known Mutations in Patients with Various Retinal Diseases., 2013, 54, 2186.		63
111	POLYPOIDAL CHOROIDAL VASCULOPATHY. Retina, 2013, 33, 686-716.	1.0	239
112	A Case of Dengue Maculopathy with Spontaneous Recovery. Case Reports in Ophthalmology, 2013, 4, 28-33.	0.3	6
113	Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema. Clinical Interventions in Aging, 2013, 8, 467.	1.3	34
114	Polypoidal choroidal vasculopathy: an update on therapeutic approaches. Journal of Ophthalmic and Vision Research, 2013, 8, 359-71.	0.7	50
115	An Update in Laser and Pharmaceutical Treatment for Polypoidal Choroidal Vasculopathy. Asia-Pacific Journal of Ophthalmology, 2012, 1, 97-104.	1.3	13
116	Association of <i>C2</i> and <i>CFB</i> Polymorphisms with Anterior Uveitis., 2012, 53, 4969.		27
117	Association of Genetic Variants on $8p21$ and $4q12$ with Age-Related Macular Degeneration in Asian Populations. , $2012, 53, 6576$.		22
118	Long-Term Follow-Up of Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization due to Choroidal Osteoma. Case Reports in Ophthalmology, 2012, 3, 200-204.	0.3	19
119	EVEREST STUDY. Retina, 2012, 32, 1453-1464.	1.0	523
120	Anti–Vascular Endothelial Growth Factor Therapy for Myopic Choroidal Neovascularization. Retina, 2012, 32, 1443-1445.	1.0	16
121	COMBINED HIGH-DOSE SUB-TENON TRIAMCINOLONE, INTRAVITREAL BEVACIZUMAB, AND LASER PHOTOCOAGULATION FOR REFRACTORY DIABETIC MACULAR EDEMA. Retina, 2012, 32, 672-678.	1.0	8
122	Long-term results of oral valganciclovir for treatment of anterior segment inflammation secondary to cytomegalovirus infection. Clinical Ophthalmology, 2012, 6, 595.	0.9	26
123	Three-year visual and anatomic results of administrating intravitreal bevacizumab in inflammatory ocular neovascularization. Canadian Journal of Ophthalmology, 2012, 47, 269-274.	0.4	41
124	Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye, 2012, 26, 1004-1011.	1.1	92
125	Choroidal neovascularization in pathological myopia. Progress in Retinal and Eye Research, 2012, 31, 495-525.	7.3	218
126	Review of Clinical Features, Microbiological Spectrum, and Treatment Outcomes of Endogenous Endophthalmitis over an 8-Year Period. Journal of Ophthalmology, 2012, 2012, 1-5.	0.6	49

#	Article	IF	CITATIONS
127	Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization. Clinical Ophthalmology, 2012, 6, 1233.	0.9	22
128	Differentiation of Exudative Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in the <i>ARMS2</i> / <i>HTRA1</i> / <i>Locus. , 2012, 53, 3175.</i>		43
129	Complement factor H and interleukin gene polymorphisms in patients with non-infectious intermediate and posterior uveitis. Molecular Vision, 2012, 18, 1865-72.	1.1	19
130	Application of multifocal visual evoked potentials in the assessment of visual dysfunction in macular diseases. Eye, 2011, 25, 1302-1309.	1.1	6
131	Revised Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy. Ophthalmology, 2011, 118, 415-422.	2.5	567
132	IMPROVEMENT IN MULTIFOCAL ELECTRORETINOGRAPHY AFTER HALF-DOSE VERTEPORFIN PHOTODYNAMIC THERAPY FOR CENTRAL SEROUS CHORIORETINOPATHY. Retina, 2011, 31, 1378-1386.	1.0	90
133	Pediatric Ocular Surface Infections: A 5-year Review of Demographics, Clinical Features, Risk Factors, Microbiological Results, and Treatment. Cornea, 2011, 30, 995-1002.	0.9	65
134	INTRAVITREAL RANIBIZUMAB WITH OR WITHOUT PHOTODYNAMIC THERAPY FOR THE TREATMENT OF SYMPTOMATIC POLYPOIDAL CHOROIDAL VASCULOPATHY. Retina, 2011, 31, 1581-1588.	1.0	79
135	IMPROVEMENT IN MULTIFOCAL ELECTRORETINOGRAPHY AFTER HALF-DOSE VERTEPORFIN PHOTODYNAMIC THERAPY FOR CENTRAL SEROUS CHORIORETINOPATHY. Retina, 2011, Publish Ahead of Print, .	1.0	1
136	Half-dose verteporfin photodynamic therapy for bullous variant of central serous chorioretinopathy: a case report. Journal of Medical Case Reports, 2011, 5, 208.	0.4	13
137	Ophthalmic manifestations and risk factors for mortality of HIV patients in the post-highly active anti-retroviral therapy era. Clinical and Experimental Ophthalmology, 2011, 39, 99-104.	1.3	41
138	Ophthalmic manifestations and risk factors for mortality of HIV patients in the post-highly active anti-retroviral therapy era: response. Clinical and Experimental Ophthalmology, 2011, 39, 919-919.	1.3	0
139	Risk Factors for Recurrence of Serous Macular Detachment in Untreated Patients with Central Serous Chorioretinopathy. Ophthalmic Research, 2011, 46, 160-163.	1.0	77
140	CFH 184G as a genetic risk marker for anterior uveitis in Chinese females. Molecular Vision, 2011, 17, 2655-64.	1.1	21
141	NOVEL AND HOMOZYGOUS BEST1 MUTATIONS IN CHINESE PATIENTS WITH BEST VITELLIFORM MACULAR DYSTROPHY. Retina, 2010, 30, 820-827.	1.0	34
142	Changes in first- and second-order multifocal electroretinography in idiopathic macular hole and their correlations with macular hole diameter and visual acuity. Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248, 477-484.	1.0	6
143	Correlation between functional and anatomical assessments by multifocal electroretinography and optical coherence tomography in central serous chorioretinopathy. Documenta Ophthalmologica, 2010, 120, 193-200.	1.0	28
144	Tyrosinase gene (<i>TYR</i>) mutations in Chinese patients with oculocutaneous albinism type 1. Clinical and Experimental Ophthalmology, 2010, 38, 37-42.	1.3	12

#	Article	IF	Citations
145	Association of NR2E3 but NotNRLM utations with Retinitis Pigmentosa in the Chinese Population., 2010, 51, 2229.		17
146	Alterations in Serum Fatty Acid Concentrations and Desaturase Activities in Bietti Crystalline Dystrophy Unaffected by <i>CYP4V2 </i> Fenotypes., 2010, 51, 1092.		42
147	Compound Heterozygosity of Two Novel Truncation Mutations in <i>RP1</i> Causing Autosomal Recessive Retinitis Pigmentosa., 2010, 51, 2236.		54
148	Photodynamic Therapy With or Without Intravitreal Triamcinolone Acetonide for Symptomatic Polypoidal Choroidal Vasculopathy. Journal of Ocular Pharmacology and Therapeutics, 2010, 26, 91-96.	0.6	25
149	Development of novel drugs for ocular diseases: possibilities for individualized therapy. Personalized Medicine, 2010, 7, 371-386.	0.8	5
150	Photodynamic therapy with verteporfin for vasoproliferative tumour of the retina. Acta Ophthalmologica, 2010, 88, 711-712.	0.6	15
151	Intravitreal Dexamethasone for Diabetic Macular Edema: A Pilot Study. Ophthalmic Surgery Lasers and Imaging Retina, 2010, 41, 26-30.	0.4	18
152	Differential pattern of RP1 mutations in retinitis pigmentosa. Molecular Vision, 2010, 16, 1353-60.	1.1	13
153	Manganese Superoxide Dismutase and Chemokine Genes Polymorphisms in Chinese Patients with Anterior Uveitis., 2009, 50, 5596.		12
154	Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. British Journal of Ophthalmology, 2009, 93, 150-154.	2.1	93
155	Factors associated with variability in response of diabetic macular oedema after intravitreal triamcinolone. Clinical and Experimental Ophthalmology, 2009, 37, 602-608.	1.3	7
156	Late appearance of an intracameral ophthalmic ointment globule after uneventful phacoemulsification. Japanese Journal of Ophthalmology, 2009, 53, 553-555.	0.9	6
157	Multifocal electroretinography changes in patients on ethambutol therapy. Eye, 2009, 23, 1707-1713.	1.1	10
158	Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease. Eye, 2009, 23, 543-548.	1.1	85
159	Panuveitis as an initial presentation of extranodal NK/T-cell lymphoma. Leukemia and Lymphoma, 2009, 50, 648-650.	0.6	4
160	PRESENCE OF CRYSTALLINE LENS AS A PROTECTIVE FACTOR FOR THE LATE DEVELOPMENT OF OPEN ANGLE GLAUCOMA AFTER VITRECTOMY. Retina, 2009, 29, 218-224.	1.0	57
161	INTRAVITREAL RANIBIZUMAB FOR THE PRIMARY TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA. Retina, 2009, 29, 750-756.	1.0	91
162	EFFICACY OF 1.25 MG VERSUS 2.5 MG INTRAVITREAL BEVACIZUMAB FOR DIABETIC MACULAR EDEMA. Retina, 2009, 29, 292-299.	1.0	81

#	Article	IF	CITATIONS
163	VISUAL OUTCOMES AND GROWTH FACTOR CHANGES OF TWO DOSAGES OF INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2009, 29, 1218-1226.	1.0	24
164	First and second-order kernel multifocal electroretinography abnormalities in acute central serous chorioretinopathy. Documenta Ophthalmologica, 2008, 116, 29-40.	1.0	25
165	Peripheral and posterior pole retinal lesions in association with high myopia: a cross-sectional community-based study in Hong Kong. Eye, 2008, 22, 209-213.	1.1	66
166	Intravitreal Bevacizumab in Inflammatory Ocular Neovascularization. American Journal of Ophthalmology, 2008, 146, 410-416.e1.	1.7	76
167	Half-Dose Verteporfin Photodynamic Therapy for Acute Central Serous Chorioretinopathy. Ophthalmology, 2008, 115, 1756-1765.	2.5	291
168	Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. British Journal of Ophthalmology, 2008, 92, 661-666.	2.1	148
169	Multifocal electroretinography: update on clinical application and future development. Expert Review of Ophthalmology, 2008, 3, 85-96.	0.3	0
170	PRIMARY 23-GAUGE TRANSCONJUNCTIVAL SUTURELESS VITRECTOMY FOR RHEGMATOGENOUS RETINAL DETACHMENT. Retina, 2008, 28, 1075-1081.	1.0	79
171	COMBINED PHOTODYNAMIC THERAPY AND INTRAVITREAL TRIAMCINOLONE FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO PUNCTATE INNER CHOROIDOPATHY OR OF IDIOPATHIC ORIGIN. Retina, 2008, 28, 71-80.	1.0	45
172	CHANGES IN AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR AND PIGMENT EPITHELIAL-DERIVED FACTOR LEVELS FOLLOWING INTRAVITREAL BEVACIZUMAB INJECTIONS FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION OR PATHOLOGIC MYOPIA. Retina, 2008, 28, 1308-1313.	1.0	77
173	SAFETY ENHANCED PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Retina, 2008, 28, 85-93.	1.0	221
174	Quality of Reporting of Key Methodological Items of Randomized Controlled Trials in Clinical Ophthalmic Journals. Ophthalmic Epidemiology, 2007, 14, 390-398.	0.8	53
175	Osteoporosis-Pseudoglioma Syndrome May Not Be Caused by Persistent Fetal Vasculature—Reply. JAMA Ophthalmology, 2007, 125, 433.	2.6	0
176	Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. British Journal of Ophthalmology, 2007, 91, 174-179.	2.1	48
177	Multifocal electroretinography in dengue fever-associated maculopathy. British Journal of Ophthalmology, 2007, 91, 1084-1085.	2.1	13
178	Results of high-density silicone oil as a tamponade agent in macular hole retinal detachment in patients with high myopia. British Journal of Ophthalmology, 2007, 91, 719-721.	2.1	50
179	Safety and Efficacy of Micro-Incisional Cataract Surgery with Bimanual Phacoemulsification for White Mature Cataract. Ophthalmologica, 2007, 221, 24-28.	1.0	6
180	The Clinical Applications of Multifocal Electroretinography: A Systematic Review. Survey of Ophthalmology, 2007, 52, 61-96.	1.7	83

#	Article	IF	CITATIONS
181	Intravitreal Triamcinolone plus Sequential Grid Laser versus Triamcinolone or Laser Alone for Treating Diabetic Macular Edema. Ophthalmology, 2007, 114, 2162-2167.e1.	2.5	109
182	Intravitreal Bevacizumab (Avastin) for Myopic Choroidal Neovascularization. Ophthalmology, 2007, 114, 2190-2196.e2.	2.5	127
183	Intravitreal Bevacizumab (Avastin) for Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy, Secondary to Punctate Inner Choroidopathy, or of Idiopathic Origin. American Journal of Ophthalmology, 2007, 143, 977-983.e1.	1.7	159
184	Genotype–Phenotype Analysis of Bietti's Crystalline Dystrophy in Patients withCYP4V2Mutations. , 2007, 48, 5212.		63
185	Spontaneous resolution of retinal pigment epithelial tears and pigment epithelial detachment following blunt trauma. Eye, 2007, 21, 891-893.	1.1	5
186	Retinal pigment epithelial tear following intravitreal ranibizumab injections for neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 245, 1225-1227.	1.0	33
187	Assessment of macular function by multifocal electroretinography following epiretinal membrane surgery with indocyanine green-assisted internal limited membrane peeling: reply. Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 245, 1239-1240.	1.0	1
188	Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 245, 1877-1880.	1.0	42
189	A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema. British Journal of Ophthalmology, 2007, 91, 199-203.	2.1	69
190	Aqueous Humor Levels of Vascular Endothelial Growth Factor and Pigment Epithelium–Derived Factor in Polypoidal Choroidal Vasculopathy and Choroidal Neovascularization. American Journal of Ophthalmology, 2006, 141, 456-462.	1.7	347
191	Acute Staphylococcus aureus wound infection after temporal clear corneal phacoemulsification. Eye, 2006, 20, 258-260.	1.1	4
192	A prospective study on trypan blue capsule staining under air vs under viscoelastic. Eye, 2006, 20, 820-825.	1.1	21
193	Visual Field and Multifocal Electroretinography and their Correlations in Patients on Hydroxychloroquine Therapy. Documenta Ophthalmologica, 2006, 112, 177-187.	1.0	54
194	Photodynamic Therapy in Macular Diseases of Asian Populations: When East Meets West. Japanese Journal of Ophthalmology, 2006, 50, 161-169.	0.9	39
195	Effect of application duration of 2% lidocaine jelly on aqueous lidocaine concentration for topical anesthesia in cataract surgery. Graefe's Archive for Clinical and Experimental Ophthalmology, 2006, 244, 1096-1100.	1.0	8
196	Assessment of macular function by multifocal electroretinography following epiretinal membrane surgery with indocyanine green-assisted internal limiting membrane peeling. Graefe's Archive for Clinical and Experimental Ophthalmology, 2006, 245, 148-154.	1.0	30
197	Indocyanine green-assisted macular pucker surgery - response Clinical and Experimental Ophthalmology, 2006, 34, 96-97.	1.3	0
198	How Evidence-Based Are Publications in Clinical Ophthalmic Journals?., 2006, 47, 1831.		35

#	Article	IF	Citations
199	Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. British Journal of Ophthalmology, 2006, 90, 869-874.	2.1	175
200	Asymmetrical Ocular Involvement and Persistent Fetal Vasculature in an Adult With Osteoporosis-Pseudoglioma Syndrome. JAMA Ophthalmology, 2006, 124, 422.	2.6	6
201	Decreasing efficacy of repeated intravitreal triamcinolone injections in diabetic macular oedema. British Journal of Ophthalmology, 2006, 90, 1137-1141.	2.1	31
202	Rapid development of severe toxic retinopathy associated with continuous intravenous deferoxamine infusion. British Journal of Ophthalmology, 2006, 90, 243-244.	2.1	19
203	Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. British Journal of Ophthalmology, 2006, 90, 337-341.	2.1	72
204	Retinal ganglion cells toxicity caused by photosensitising effects of intravitreal indocyanine green with illumination in rat eyes. British Journal of Ophthalmology, 2006, 90, 99-102.	2.1	47
205	Results of Trabeculectomy With Adjunctive Intraoperative Mitomycin C in Chinese Patients With Glaucoma. Ophthalmic Surgery Lasers and Imaging Retina, 2006, 37, 33-41.	0.4	19
206	Prioritization of cataract surgery: Visual analogue scale versus scoring system. ANZ Journal of Surgery, 2005, 75, 587-592.	0.3	8
207	Multifocal electroretinogram and optical coherence tomography of commotio retinae and traumatic macular hole. Eye, 2005, 19, 219-221.	1.1	13
208	Phacoemulsification with intravitreal triamcinolone in patients with cataract and coexisting diabetic macular oedema: a 6-month prospective pilot study. Eye, 2005, 19, 885-890.	1.1	60
209	Immediate pars plana vitrectomy for dislocated intravitreal lens fragments during cataract surgery. Eye, 2005, 19, 1157-1162.	1.1	32
210	Epiretinal membrane surgery with or without internal limiting membrane peeling. Clinical and Experimental Ophthalmology, 2005, 33, 379-385.	1.3	162
211	Extensive submacular haemorrhage in polypoidal choroidal vasculopathy managed by sequential gas displacement and photodynamic therapy: a pilot study of one-year follow up. Clinical and Experimental Ophthalmology, 2005, 33, 611-618.	1.3	27
212	Black diaphragm aniridia intraocular lens for aniridia and albinism. Graefe's Archive for Clinical and Experimental Ophthalmology, 2005, 243, 501-504.	1.0	27
213	Vitrectomy and gas tamponade without internal limiting membrane peeling for myopic foveoschisis. British Journal of Ophthalmology, 2005, 89, 1180-1183.	2.1	94
214	Multifocal electroretinogram demonstrated macular toxicity associated with ethambutol related optic neuropathy. British Journal of Ophthalmology, 2005, 89, 774-775.	2.1	24
215	Choroidal neovascularisation in pathological myopia: an update in management. British Journal of Ophthalmology, 2005, 89, 1522-1528.	2.1	86
216	The effects of indocyanine green and endoillumination on rabbit retina: an electroretinographic and histological study. British Journal of Ophthalmology, 2005, 89, 897-900.	2.1	26

#	Article	IF	Citations
217	Multifocal Electroretinographic Changes in Patients Receiving Hydroxychloroquine Therapy. American Journal of Ophthalmology, 2005, 140, 794-807.e1.	1.7	104
218	Retinectomy for intractable glaucoma. British Journal of Ophthalmology, 2004, 88, 1352-1353.	2.1	2
219	Trypan blue- and indocyanine green-assisted epiretinal membrane surgery: clinical and histopathological studies. Eye, 2004, 18, 882-888.	1.1	42
220	Physicians' perceptions towards the impact of and willingness to pay for clinical computerization in Hong Kong. International Journal of Medical Informatics, 2004, 73, 403-414.	1.6	6
221	Do doctors act on their self-reported intention to computerize? A follow-up population-based survey in Hong Kong. International Journal of Medical Informatics, 2004, 73, 415-431.	1.6	8
222	Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy. Ophthalmology, 2004, 111, 1576-1584.	2.5	278
223	Internal limiting membrane staining with various concentrations of indocyanine green dye under air in macular surgeries: Author Reply. American Journal of Ophthalmology, 2004, 137, 589-590.	1.7	0
224	Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy. American Journal of Ophthalmology, 2004, 137, 826-833.	1.7	113
225	Indocyanine green-assisted internal limiting membrane removal in epiretinal membrane surgery: A clinical and histologic study. American Journal of Ophthalmology, 2004, 138, 194-199.	1.7	95
226	Laser photocoagulation of indocyanine green aniographically identified feeder vessels to idiopathic polypoidal choroidal vasculopathy. American Journal of Ophthalmology, 2004, 138, 693-694.	1.7	5
227	Effects of trypan blue on cell viability and gene expression in human retinal pigment epithelial cells. British Journal of Ophthalmology, 2004, 88, 1590-1594.	2.1	63
228	Macular hole surgery with or without indocyanine green stained internal limiting membrane peeling. Clinical and Experimental Ophthalmology, 2003, 31, 470-475.	1.3	51
229	Internal limiting membrane staining with various concentrations of indocyanine green dye under air in macular surgeries. American Journal of Ophthalmology, 2003, 136, 223-230.	1.7	63
230	Photodynamic therapy with verteporfin in laser-induced choroidal neovascularization. American Journal of Ophthalmology, 2003, 136, 565-567.	1.7	8
231	latrogenic punctate chorioretinopathy after internal limiting membrane peeling. American Journal of Ophthalmology, 2003, 136, 396.	1.7	0
232	Epiretinal membrane formation with internal limiting membrane wrinkling after Nd:YAG laser membranotomy in valsalva retinopathy. American Journal of Ophthalmology, 2003, 136, 763-766.	1.7	77
233	Treatment of choroidal neovascularization in central serous chorioretinopathy by photodynamic therapy with verteporfin. American Journal of Ophthalmology, 2003, 136, 836-845.	1.7	74
234	Photodynamic therapy with verteporfin for subfoveal idiopathic choroidal neovascularization. Ophthalmology, 2003, 110, 2395-2402.	2.5	60

#	Article	IF	Citations
235	Is ophthalmology evidence based? A clinical audit of the emergency unit of a regional eye hospital. British Journal of Ophthalmology, 2003, 87, 385-390.	2.1	24
236	Indocyanine green assisted retinal internal limiting membrane removal in stage 3 or 4 macular hole surgery. British Journal of Ophthalmology, 2003, 87, 71-74.	2.1	107
237	Penetrating keratoplasty in children: visual and graft outcome. British Journal of Ophthalmology, 2003, 87, 1212-1214.	2.1	54
238	Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. British Journal of Ophthalmology, 2003, 87, 1453-1458.	2.1	371
239	Internal limiting membrane removal in macular hole surgery for severely myopic eyes: a case-control study. British Journal of Ophthalmology, 2003, 87, 885-889.	2.1	55
240	Laser induced chorioretinal venous anastomosis in ischaemic central retinal vein occlusion. British Journal of Ophthalmology, 2003, 87, 1043-1044.	2.1	12
241	Effect of Indocyanine Green and Illumination on Gene Expression in Human Retinal Pigment Epithelial Cells., 2003, 44, 370.		113
242	Correlation of Clinical and Optical Coherence Tomography Findings in Postoperative Macular Hole Closure Status. Ophthalmic Surgery Lasers and Imaging Retina, 2003, 34, 25-32.	0.4	5
243	Polypoidal choroidal vasculopathy in Chinese patients. British Journal of Ophthalmology, 2002, 86, 892-897.	2.1	143
244	Acrylic intraocular lens placement in conjunction with pars plana vitrectomy. American Journal of Ophthalmology, 2002, 133, 586.	1.7	0
245	ILM peeling in macular hole surgery. Ophthalmology, 2002, 109, 822.	2.5	4
246	Pars plana vitrectomy in the management of retained intravitreal lens fragments after cataract surgery. Clinical and Experimental Ophthalmology, 2002, 30, 399-403.	1.3	36
247	Indocyanine green staining and removal of internal limiting membrane in macular hole surgery: histology and outcome. American Journal of Ophthalmology, 2001, 132, 178-183.	1.7	192
248	Sub-Tenon's injection for posterior segment surgery. Ophthalmology, 2001, 108, 1006-1007.	2.5	1
249	Disinfection of vacuum control manifold to prevent postoperative endophthalmitis. Ophthalmology, 2001, 108, 636.	2.5	0
250	Massive subretinal haemorrhage associated with central serous chorioretinopathy. Eye, 2001, 15, 121-123.	1.1	1
251	Stenotrophomonas maltophilia endophthalmitis after penetrating injury by a wooden splinter. Eye, 2001, 15, 353-354.	1.1	19
252	Progression of diabetic retinopathy after endophthalmitis. Ophthalmology, 2000, 107, 619.	2.5	6

#	Article	IF	CITATIONS
253	Primary Orbital Ewing Sarcoma in a Middle-aged Woman. JAMA Ophthalmology, 2000, 118, 592.	2.6	2